Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 26, Issue 21, pp. 5631-5637
PubMed
Published By
Print ISSN
Online ISSN
History
- Received February 21, 2020
- Revision received May 15, 2020
- Accepted July 24, 2020
- Published first July 28, 2020.
Article Versions
- Previous version (July 28, 2020 - 06:10).
- Previous version (August 14, 2020 - 08:13).
- Previous version (September 23, 2020 - 06:25).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- John W. Moroney1,*,
- John Powderly2,
- Christopher H. Lieu3,
- Johanna C. Bendell4,
- S. Gail Eckhardt5,
- Ching-Wei Chang6,
- Luciana Molinero6,
- Jessica Spahn6,
- Patrick Williams6,
- Yvonne G. Lin6, and
- F. Stephen Hodi7
- 1Department of Obstetrics and Gynecology, The University of Chicago, Chicago, Illinois.
- 2Carolina BioOncology Institute, Huntersville, North Carolina.
- 3Division of Medical Oncology, University of Colorado, Aurora, Colorado.
- 4Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee.
- 5Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
- 6Genentech Inc, South San Francisco, California.
- 7Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts.
- ↵*Corresponding Author:
John W. Moroney, University of Chicago, IL 60637. Phone: 773-702-6721; Fax: 177-3702-5411; E-mail: jwmoroney{at}bsd.uchicago.edu
November 2020
Volume 26, Issue 21
Volume 26, Issue 21
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study
Jump to section
Advertisement